Harbor Investment Advisory LLC Has $239,000 Position in Novo Nordisk A/S (NYSE:NVO)

Harbor Investment Advisory LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 110.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,858 shares of the company’s stock after purchasing an additional 977 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $239,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Pacific Center for Financial Services increased its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. First PREMIER Bank bought a new stake in Novo Nordisk A/S in the 1st quarter valued at approximately $25,000. CNB Bank bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management raised its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. increased its stake in Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NVO stock traded up $0.29 during midday trading on Monday, reaching $142.25. 2,988,899 shares of the company were exchanged, compared to its average volume of 4,459,286. The firm has a market capitalization of $638.35 billion, a price-to-earnings ratio of 48.95, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The business has a 50-day moving average price of $132.94 and a two-hundred day moving average price of $122.05. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $144.50. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The business had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.41 EPS for the current year.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent research reports. Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $145.67.

Check Out Our Latest Research Report on Novo Nordisk A/S

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Recommended Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.